[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research[1][2].
in vivo
GIPR-/- mice have higher blood glucose levels and impaired initial insulin response after oral glucose loading. In GIPR+/+ mice, a high-fat diet did not increase postprandial intake blood glucose levels, whereas it significantly increased in GIPR-/- mice[2].
References
[1] LaPelusa A, et al. Biochemistry, Bombesin[M]//StatPearls [Internet]. StatPearls Publishing, 2021. [2] K Miyawaki, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14843-7. DOI:10.1073/pnas.96.26.14843
[TYR0] GASTRIC INHIBITORY PEPTIDE (23-42), HUMAN Supplier
![[TYR0] GASTRIC INHIBITORY PEPTIDE (23-42), HUMAN Structure](/StructureFile/ChemBookStructure2/GIF/CB5754809.gif)